ODM-212

About Orion

Orion Corporation is a publicly traded, fully integrated pharmaceutical company with a 100+ year legacy, headquartered in Espoo, Finland. Its strategy is built on deep therapeutic expertise in oncology and pain, a vertically integrated model encompassing API manufacturing, and a global commercial presence in ~100 countries. The company is advancing a promising clinical pipeline, including the Phase 2 TEAD inhibitor ODM-212, while generating stable revenue from its established portfolio and contract manufacturing operations.

About Orion Corporation

Orion Corporation is a century-old, publicly traded Finnish pharmaceutical leader with a dual-pillar strategy: developing proprietary drugs in CNS, oncology, and respiratory diseases, and operating a leading contract manufacturing (Fermion CDMO) business. Its major achievement is the global success of Nubeqa® (darolutamide) for prostate cancer, developed with Bayer, which anchors its growing oncology franchise. The company's vertically integrated operations, substantial pipeline, and resilient revenue model position it for sustainable growth in specialty pharma and the CDMO sector.

Therapeutic Areas